10/26/2026
FDA psychedelics docket draws mixed stakeholder responses
Stakeholders express varied opinions on FDA's recent psychedelics docket, highlighting diverse perspectives.
Topic archive
regulation
11 stories
10/9/2026
FDA seeks public input on ibogaine trials
Gabon aims to secure benefits from rising ibogaine demand
10/5/2026
FDA considers framework for ibogaine trials
The FDA is evaluating guidelines for ibogaine clinical trials.
9/10/2026
Rhelion Life Sciences launches ibogaine stability program
Filament Health begins stability program for IBEX011 amid rising ibogaine demand.
9/4/2026
Federal report urges states to prepare for psychedelics
States advised to anticipate FDA approval of psychedelics for medical use.
8/26/2026
Psychedelic tourism raises safety concerns
Recent deaths highlight risks in unregulated psychedelic retreats.
8/26/2026
Americans face risks at overseas psychedelic clinics
Ibogaine treatments in Mexico raise safety concerns for U.S. patients.
8/16/2026
Ibogaine shows promise for treating brain disorders
Research highlights ibogaine's potential in opioid addiction and multiple sclerosis.
8/7/2026
Ibogaine treatment explored for veterans
Ibogaine's potential in treating PTSD and opioid addiction in veterans examined.
7/24/2026
Ibogaine may gain U.S. access under Trump administration
The Trump administration considers making ibogaine available for therapeutic use.
7/23/2026
McCaul supports NDAA amendment for veteran ibogaine access
The amendment aims to expand treatment options for PTSD and addiction.